- Our game changing proprietary BiXAb® technology enables BIOMUNEX to discover and develop immunotherapies for several cancer types. Our BiXAb® technology offers key properties of an ideal bispecific platform: rapid design and modularity; excellent drug like properties; high yields and cost-effective manufacturability; multi-specific capability and versatility.
- Our rapidly evolving pipeline will soon enable BIOMUNEX to be a clinical stage company. The most advanced BiXAb® candidates, developed for immuno-oncology applications, have demonstrated superior in vitro and in vivo efficacy in solid tumors and hematological malignancies. BIOMUNEX also initiated the discovery and development of additional BiXAb®s for disruptive approaches in immuno-oncology in collaboration with renowned academic institutions such as the Institut Curie in Paris.
- The BiXAb® technology and pipeline has been validated by licensing deals signed with industrial partners for development of bi- and multi-specific antibodies:
The management team is made up of an experienced group of international C-level executives and drug developers from the pharma and biotech industries, with extensive scientific expertise in oncology.
BIOMUNEX is currently expanding its team by recruiting additional world-class top executives and scientists. BIOMUNEX has established strategic and scientific boards consisting of key opinion leaders in their fields.